Back

Moderna-Merck cancer vaccine breakthrough adds more than $50 billion in value

Verifying
  • Moderna and Merck’s mRNA-4157 met its primary endpoint in a Phase 3 melanoma trial.
  • 177%: Moderna shares surged in one day, adding approximately $44 billion in market value.
  • Tempus AI agreed to acquire Personalis for $16.25 per share on July 20.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.